Free VIDEO B-ROLL AVAILABLE VIA CNW - Bexsero®: First Vaccine to Prevent Meningococcal Serogroup B (MenB) Now Available in Canada

Free VIDEO B-ROLL AVAILABLE VIA CNW - Bexsero®: First Vaccine to Prevent Meningococcal Serogroup B (MenB) Now Available in Canada


TORONTO, Feb. 26, 2014 /CNW/ - The following B-Roll is available by
Video On-Demand web download:


STORY SUMMARY: Novartis announced today that Bexsero® (Multicomponent Meningococcal B
Vaccine [recombinant, adsorbed]) is now available to doctors and
pharmacists across Canada. The vaccine is approved for use in
individuals from two months through 17 years of age in Canada. Infants,
toddlers and adolescents are at the greatest risk of meningococcal
serogroup B (MenB) infection. Bexsero® is the first broad-coverage
vaccine to help protect against MenB disease. Prior to Bexsero®,
vaccines were only available to help protect against meningococcal
strains A, C, W and Y.


Full Press Release:http://www.newswire.ca/en/story/1313097/bexsero-first-vaccine-to-prevent-meningococcal-serogroup-b-menb-now-available-in-canada

WEB Video Preview and Download link:

http://cnw.pathfireondemand.com/viewpackage.action?packageid=775



TIME OF POSTING: Available Now

DATE OF POSTING: 02/26/2014






All video can be viewed by clicking on the link. Broadcast quality video
is available for download by accredited journalists. Please contact video@newswire.ca for access.


STATIONS, FOR FURTHER INFORMATION, PLEASE CALL:


Abigail Bueno

Weber Shandwick

416 642 7893
abueno@webershandwick.com


For assistance with Video On-Demand, please contact CNW at video@newswire.ca or (416) 863-5612.



CNW Video On-Demand http://cnw.pathfireondemand.com provides free, secure and easy-to-use broadcast quality material direct
from our website to accredited journalists worldwide.



This material is offered for free and unrestricted news use.



CNW VIDEO SERVICES.


SOURCE Novartis Pharmaceuticals Canada Inc.

Novartis Pharmaceuticals Canada Inc.

CONTACT: CNW VIDEO SERVICES, TORONTO (416) 863-5612


-------
Profile: intent